Clinical pharmacology of dobutamine and dopamine in preterm neonates

Detalhes bibliográficos
Autor(a) principal: Pacifici,Gian Maria
Data de Publicação: 2014
Tipo de documento: Artigo
Idioma: eng
Título da fonte: MedicalExpress (São Paulo. Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000500275
Resumo: Dobutamine is a β1 selective stimulant. β Receptor agonists are used to stimulate the rate and the force of cardiac contraction. The chronotropic effect is useful for the treatment of arrhythmias whereas the inotropic effect is useful to augment the myocardial contractility. Dobutamine is about four times as potent as dopamine in stimulating myocardial contractility in low concentrations and increases left ventricular output in the hypotensive preterm infants. Dobutamine possesses a center of asymmetry. The (-)-isomer of dobutamine is a potent agonist of α1 receptors and is capable of causing marked pressor responses. In contrast, (+)-dobutamine is a potent α1 receptor antagonist which can block the effects of (-)-dobutamine. Dobutamine is relatively cardioselective at dosages used in clinical practice with its main action being on β1-adrenergic receptors. Dobutamine and dopamine undergo intense metabolism in neonates where they are conjugated with sulphate and O-methylated. The clearance and the half-life of dobutamine and dopamine range over one order of magnitude in neonates. Dopamine is widely used to increase blood pressure, cardiac output, urine output and peripheral perfusion in neonates with shock and cardiac failure. Dopamine is more effective than dobutamine in the short-term treatment of systemic hypotension in preterm infants. High doses of dopamine cause vasoconstriction, increase systemic vascular resistance, and, eventually, decrease renal blood flow. Treatment with dobutamine is associated with a significantly greater increase in left ventricular output in the single study reporting that outcome. Dobutamine is indicated for the short-term treatment of cardiac decompensation.
id METC-1_2e8b80f470d2c00f7add6290dfdd0366
oai_identifier_str oai:scielo:S2358-04292014000500275
network_acronym_str METC-1
network_name_str MedicalExpress (São Paulo. Online)
repository_id_str
spelling Clinical pharmacology of dobutamine and dopamine in preterm neonatesdobutaminedopaminehypotensionmetabolismneonatepharmacokineticsDobutamine is a β1 selective stimulant. β Receptor agonists are used to stimulate the rate and the force of cardiac contraction. The chronotropic effect is useful for the treatment of arrhythmias whereas the inotropic effect is useful to augment the myocardial contractility. Dobutamine is about four times as potent as dopamine in stimulating myocardial contractility in low concentrations and increases left ventricular output in the hypotensive preterm infants. Dobutamine possesses a center of asymmetry. The (-)-isomer of dobutamine is a potent agonist of α1 receptors and is capable of causing marked pressor responses. In contrast, (+)-dobutamine is a potent α1 receptor antagonist which can block the effects of (-)-dobutamine. Dobutamine is relatively cardioselective at dosages used in clinical practice with its main action being on β1-adrenergic receptors. Dobutamine and dopamine undergo intense metabolism in neonates where they are conjugated with sulphate and O-methylated. The clearance and the half-life of dobutamine and dopamine range over one order of magnitude in neonates. Dopamine is widely used to increase blood pressure, cardiac output, urine output and peripheral perfusion in neonates with shock and cardiac failure. Dopamine is more effective than dobutamine in the short-term treatment of systemic hypotension in preterm infants. High doses of dopamine cause vasoconstriction, increase systemic vascular resistance, and, eventually, decrease renal blood flow. Treatment with dobutamine is associated with a significantly greater increase in left ventricular output in the single study reporting that outcome. Dobutamine is indicated for the short-term treatment of cardiac decompensation.Mavera Edições Técnicas e Científicas Ltda2014-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000500275MedicalExpress v.1 n.5 2014reponame:MedicalExpress (São Paulo. Online)instname:Mavera Edições Científicas e Técnicas Ltda-MEinstacron:METC10.5935/MedicalExpress.2014.05.12info:eu-repo/semantics/openAccessPacifici,Gian Mariaeng2016-05-12T00:00:00Zoai:scielo:S2358-04292014000500275Revistahttp://www.medicalexpress.net.brhttps://old.scielo.br/oai/scielo-oai.php||medicalexpress@me.net.br2358-04292318-8111opendoar:2016-05-12T00:00MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-MEfalse
dc.title.none.fl_str_mv Clinical pharmacology of dobutamine and dopamine in preterm neonates
title Clinical pharmacology of dobutamine and dopamine in preterm neonates
spellingShingle Clinical pharmacology of dobutamine and dopamine in preterm neonates
Pacifici,Gian Maria
dobutamine
dopamine
hypotension
metabolism
neonate
pharmacokinetics
title_short Clinical pharmacology of dobutamine and dopamine in preterm neonates
title_full Clinical pharmacology of dobutamine and dopamine in preterm neonates
title_fullStr Clinical pharmacology of dobutamine and dopamine in preterm neonates
title_full_unstemmed Clinical pharmacology of dobutamine and dopamine in preterm neonates
title_sort Clinical pharmacology of dobutamine and dopamine in preterm neonates
author Pacifici,Gian Maria
author_facet Pacifici,Gian Maria
author_role author
dc.contributor.author.fl_str_mv Pacifici,Gian Maria
dc.subject.por.fl_str_mv dobutamine
dopamine
hypotension
metabolism
neonate
pharmacokinetics
topic dobutamine
dopamine
hypotension
metabolism
neonate
pharmacokinetics
description Dobutamine is a β1 selective stimulant. β Receptor agonists are used to stimulate the rate and the force of cardiac contraction. The chronotropic effect is useful for the treatment of arrhythmias whereas the inotropic effect is useful to augment the myocardial contractility. Dobutamine is about four times as potent as dopamine in stimulating myocardial contractility in low concentrations and increases left ventricular output in the hypotensive preterm infants. Dobutamine possesses a center of asymmetry. The (-)-isomer of dobutamine is a potent agonist of α1 receptors and is capable of causing marked pressor responses. In contrast, (+)-dobutamine is a potent α1 receptor antagonist which can block the effects of (-)-dobutamine. Dobutamine is relatively cardioselective at dosages used in clinical practice with its main action being on β1-adrenergic receptors. Dobutamine and dopamine undergo intense metabolism in neonates where they are conjugated with sulphate and O-methylated. The clearance and the half-life of dobutamine and dopamine range over one order of magnitude in neonates. Dopamine is widely used to increase blood pressure, cardiac output, urine output and peripheral perfusion in neonates with shock and cardiac failure. Dopamine is more effective than dobutamine in the short-term treatment of systemic hypotension in preterm infants. High doses of dopamine cause vasoconstriction, increase systemic vascular resistance, and, eventually, decrease renal blood flow. Treatment with dobutamine is associated with a significantly greater increase in left ventricular output in the single study reporting that outcome. Dobutamine is indicated for the short-term treatment of cardiac decompensation.
publishDate 2014
dc.date.none.fl_str_mv 2014-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000500275
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000500275
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/MedicalExpress.2014.05.12
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Mavera Edições Técnicas e Científicas Ltda
publisher.none.fl_str_mv Mavera Edições Técnicas e Científicas Ltda
dc.source.none.fl_str_mv MedicalExpress v.1 n.5 2014
reponame:MedicalExpress (São Paulo. Online)
instname:Mavera Edições Científicas e Técnicas Ltda-ME
instacron:METC
instname_str Mavera Edições Científicas e Técnicas Ltda-ME
instacron_str METC
institution METC
reponame_str MedicalExpress (São Paulo. Online)
collection MedicalExpress (São Paulo. Online)
repository.name.fl_str_mv MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-ME
repository.mail.fl_str_mv ||medicalexpress@me.net.br
_version_ 1754734596611637248